Treated 20 th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study Submitted First-of-Kind IND to FDA for Universal Off-the-Shelf NK Cell Product FT500 Licensed Novel CAR Constructs from Memorial Sloan Kettering Cancer Center for Off-the-ShelfRead All »
SAN DIEGO , July 30, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and liveRead All »
SAN DIEGO , June 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief ExecutiveRead All »
Dr. Michel Sadelain to Present Preclinical Data from iPSC-derived, TCR-less, CAR T-cell Collaboration at ASGCT 2018 SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellularRead All »
No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 SubmissionRead All »
SAN DIEGO , May 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and liveRead All »
SAN DIEGO , May 02, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Chief Scientific Officer, willRead All »
Off-the-Shelf CAR T-cell Product Candidate Designed to Target CD19-positive Tumor Cells and to Overcome Antigen Escape Manufacture from Master iPSC Line Enables Mass Production and Broad Accessibility without Patient Restriction AACR Press Program to Begin Today at 8:30 a.m.Read All »
Stable Disease with Tumor Shrinkage Reported in Subject 2 Following Single Dose of NK100 SAN DIEGO , March 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancerRead All »
No Events of Cancer Relapse No ProTmune-related Serious Adverse Events Reported by Investigators SAN DIEGO , March 19, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies forRead All »
DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.